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A 12-week, double-blind, placebo-controlled, multicenter study evaluated the efficacy and safety
of flexible-dose sildenafil citrate (Viagra1) treatment (25, 50 or 100 mg) in Brazilian and Mexican
men with erectile dysfunction (ED) of broad-spectrum etiology. Efficacy was assessed on the basis
of responses to the 15-item International Index of Erectile Function (IIEF) questionnaire,
completed at baseline and after 12 weeks of treatment. At end point, mean scores for all IIEF
domains of sexual function (erectile function, orgasmic function, sexual desire, intercourse
satisfaction and overall satisfaction) were significantly (P< 0.0001) higher in the sildenafil group
(n¼ 109) than in the placebo group (n¼ 105). These findings confirm the significant increases in
frequency of penetration and frequency of maintained erections reported previously. Sildenafil
treatment was well tolerated. The most common adverse events were headache and flushing. In
conclusion, sildenafil is a well-tolerated and effective treatment for ED of broad-spectrum etiology
in Latin American men.
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Introduction
Sildenafil citrate (Viagra1) was approved for the oral
treatment of erectile dysfunction (ED) in Brazil and
Mexico in 1998. In men with ED, sildenafil facil-
itates penile erection during sexual stimulation by
selectively inhibiting cyclic guanosine monopho-
sphate (cGMP)-specific phosphodiesterase type 5
(PDE5), the enzyme responsible for the catabolism of
cGMP in the corpus cavernosum, thereby enhancing
the nitric oxide=cGMP mechanism of penile erec-
tion.1 The safety and efficacy of sildenafil as an oral
treatment for ED was established by numerous
double-blind, placebo-controlled clinical trials con-
ducted initially in the USA, UK and Europe2,3 and
subsequently in other countries worldwide.4 Epide-
miological data suggesting a prevalence of ED of
approximately 30% to 40% among Latin American
men indicate the need for an effective treatment for
ED in this population.5,6
The present clinical trial was conducted to
evaluate the safety and efficacy of oral flexible-dose
sildenafil treatment over a 12-week period in Latin
American men with ED of broad-spectrum etiology.
As in the initial controlled clinical evaluations of
sildenafil for the treatment of ED,2,3 efficacy was
assessed primarily on the basis of responses to the
15-item International Index of Erectile Function
(IIEF) questionnaire,7 with the primary efficacy
variables being responses to question 3 (Q3,
frequency of penetration) and question 4 (Q4,
frequency of maintained erection after penetration).
The efficacy of sildenafil treatment was also
assessed on the basis of responses to other questions
of the IIEF, responses to a global efficacy question
(GEQ) and responses to questions on an event log
(secondary efficacy variables). Glina et al have
previously reported the primary efficacy outcomes
of this study as well as global efficacy outcomes
derived from analysis of responses to GEQ and event
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log data.8 We now report additional efficacy out-
comes of the study, specifically, the effects of
sildenafil treatment on IIEF domains of male sexual
function. These findings extend and further support
the efficacy results reported previously.
Patients and methods
Study design and patients
This was a double-blind, randomized, placebo-
controlled, multicenter, parallel-group, flexible-dose
study of oral sildenafil taken as required (but not
more than once daily) approximately 1 h before
anticipated sexual activity. The study was con-
ducted at six clinics in Mexico and nine clinics in
Brazil. The study protocol was approved by local
ethics committees. All study participants gave
written informed consent.
Male outpatients aged 18 y or older with a primary
clinical diagnosis of ED of  6 months’ duration and
who were in a stable, heterosexual relationship for a
duration of  6 months were eligible for enrolment
in the study. Excluded were subjects with genital
anatomical deformities; ED secondary to spinal cord
injury; primary diagnosis of other sexual disorders,
including hypoactive sexual desire; prolactin level
> 3 times the upper limit of the normal range or free
testosterone level > 20% below the lower limit of the
normal range; uncontrolled major psychiatric dis-
order; diabetes mellitus that was poorly controlled
or associated with untreated proliferative retinopa-
thy; history of stroke, myocardial infarction or
significant cardiovascular disease within the pre-
vious 6 months; hypotension or hypertension (blood
pressure > 170=100 mmHg); history of major hema-
tological, renal, or hepatic abnormalities, alcoholism
or substance abuse; or retinitis pigmentosa. Patients
receiving nitrates or nitric oxide donors were
excluded.
During a screening period (week-4), all study
participants underwent physical examination, med-
ical history taking, 12-lead electrocardiogram (ECG),
measurement of vital signs (sitting blood pressure
and heart rate) and laboratory safety tests (hematol-
ogy and biochemistry). Sitting blood pressure and
heart rate were also measured at weeks 0, 2, 4, 8
and 12, and physical examination, 12-lead ECG
and laboratory safety tests were repeated after the
12-week treatment period.
Aftera4-week,treatment-free,run-inperiod,patients
were randomized to receive 12 weeks of double-blind
treatment with either sildenafil or placebo. All patients
were started on a 50-mg dose of sildenafil or matching
placebo for a period of two weeks, after which (at weeks
2, 4, 8 or 12), the dose could be increased to 100 mg
because of lack of efficacy or decreased to 25 mg if the
patient did not tolerate the current higher dose.
Concurrent use of vacuum devices, intracavernosal
injection, testosterone or any other medications or
therapies to treat ED was not permitted.
Efficacy assessments
Efficacy was assessed on the basis of self-reported
responses to the 15-item IIEF, a validated question-
naire that addresses five domains of male sexual
function.7 Patients completed the IIEF at baseline
(week 0) and at the end of 12 weeks of double-blind
treatment. The primary efficacy variables were Q3
and Q4, as described previously.8 Other efficacy
measures were a GEQ asking if treatment improved
participants’ erections and an event log in which
men recorded the date and dose of study medication
and=or engagement in sexual activity, presence=
absence of sexual stimulation and whether sexual
intercourse was successful=unsuccessful.
Table 1 International Index of Erectile Function (IIEF) domains of male sexual function
Domain Total score range Item in each domain
Erectile function 1 – 30 Q1: ability to achieve an erection
Q2: frequency of erections hard enough for penetration
Q3: frequency of penetration
Q4: ability to maintain an erection after penetration
Q5: ability to maintain erection to sexual intercourse completion
Q15: confidence in getting and maintaining erection
Orgasmic function 0 – 10 Q9: frequency of ejaculation
Q10: frequency of orgasm
Sexual desire 2 – 10 Q11: frequency of sexual desire
Q12: level of sexual desire
Intercourse satisfaction 0 – 15 Q6: frequency of attempted sexual intercourse
Q7: satisfaction of sexual intercourse
Q8: enjoyment of sexual intercourse
Overall satisfaction 2 – 10 Q13: satisfaction with sex life
Q14: satisfaction with sexual relationship with partner
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Responses to the 15 questions of the IIEF were
grouped into domains addressing five major aspects
of male sexual function (Table 1): (i) erectile
function; (ii) orgasmic function; (iii) sexual desire;
(iv) intercourse satisfaction; and (v) overall satisfac-
tion with sex life. All of the responses to the IIEF
questions were rated on a 5-point scale, with a score
of 1 representing the worst response and 5 the best
response. For example, in response to questions
related to erectile function (Q1 – 4), orgasmic func-
tion (Q9 and Q10), sexual desire (Q11) or inter-
course satisfaction (Q7), a score of 1 corresponded to
a response of ‘almost never=never’ and a score of 5 to
a response of ‘almost always=always’. For overall
satisfaction (Q13 and Q14), a score of 1 corre-
sponded to a response of ‘very dissatisfied’ and a
score of 5 to ‘very satisfied.’ A score of 0 (for Q1 – 10)
corresponded to ‘no sexual activity’, ‘no sexual
stimulation’ or ‘did not attempt intercourse.’ The
domain scores were computed by adding the scores
for the individual questions in each domain.
A subject’s scores were eliminated from the calcula-
tion of a particular domain score if any item of that
domain was missing.
Safety assessments
Safety was assessed primarily by adverse events
occurring during treatment or within seven days of
the end of treatment. The investigator assessed the
severity of each adverse event and its relationship to
study medication. Abnormal changes from screen-
ing in laboratory safety tests, physical examination,
12-lead ECG, heart rate or blood pressure were
additional safety parameters. All patients who took
at least one dose of study medication were included
in the safety analysis.
Statistical analysis
All subjects who were randomized, took at least one
dose of study medication and had at least one post-
randomization efficacy evaluation were included in
the analysis (intent-to-treat population). The five
IIEF domains were analyzed using analysis of
covariance (ANCOVA), including terms for treat-
ment, baseline, center, treatment by baseline inter-
action and treatment by center interaction. As
described previously, the primary efficacy variables
(IIEF Q3 and Q4) were analyzed using ANCOVA, the
GEQ was analyzed using logistic regression and the
proportion of successful attempts at intercourse
derived from event log data were estimated using
an ANCOVA model.8 All statistical analyses were
performed using SAS1 version 6.12 (Cary, NC).9
Statistical tests were two-sided and tested at the 5%
significance level.
Results
Across the 15 centers, a total of 245 patients, 124
from Mexico and 121 from Brazil, were randomized
to treatment with sildenafil (n¼ 124) and placebo
(n¼ 121). The two treatment groups had similar
demographics at baseline (Table 2). The most
common concomitant medical conditions were
Table 2 Patient demographics at baseline
Sildenafil (n¼124) Placebo (n¼ 121)
Mean age, y (range) 58 (28 – 85) 55 (27 – 84)
Mean time since diagnosis, y (range) 3.7 (0.5 – 25.6) 3.4 (0.5 – 21.7)
Race, n (%)
Hispanic 60 (48.4) 57 (47.1)
White 60 (48.4) 58 (47.9)
Other 4 (3.2) 6 (5)
Etiology of ED, n (%)
Organic 51 (41.2) 50 (41.3)
Psychogenic 25 (20.2) 18 (14.9)
Mixed 48 (38.7) 53 (43.8)
Concomitant medical disorders, n (%)
Hypertension, unspecified essential 36 (29) 29 (24)
Diabetes mellitus 30 (24) 22 (18)
Prostatic hyperplasia 6 (5) 8 (7)
Visual disturbance, unspecified 5 (4.0) 7 (5.8)
Concomitant medications, n (%)
Antihypertensive agents 29 (23.4) 30 (24.8)
Antidiabetic agents 27 (21.8) 27 (22.3)
Beta-adrenoceptor blockers 11 (8.9) 9 (7.4)
Sedatives, hypnotics, anxiolytics 7 (5.6) 4 (3.3)
Anti-inflammatory analgesics 6 (4.8) 13 (10.7)
Antihyperlipidemic agents 6 (4.8) 4 (3.3)
Diuretics 6 (4.8) 6 (5)
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hypertension and diabetes mellitus and subse-
quently, the most common concomitant medications
were antihypertensives and antidiabetic agents.
The sildenafil treatment group took a median of
36 doses over a median of 84.5 days and the placebo
group took a median of 32 doses over a median of 84
days. The majority of study patients preferred the
highest dose of study drug. Of the 124 patients in the
sildenafil group, four (3%) were taking 25 mg, 48
(39%) were taking 50 mg and 71 (57%) were taking
100 mg at study end or last dose dispensed.
Overall, 15 of 124 (12%) patients in the sildenafil
group and 16 of 121 (13%) patients in the placebo
group prematurely discontinued the study. Discon-
tinuations were treatment related in four (3%)
patients receiving sildenafil and three (3%) patients
receiving placebo. These discontinuations were due
to adverse events (severe transient headache in one
patient receiving sildenafil) or lack of efficacy
(sildenafil, n¼ 3; placebo, n¼ 3).
Efficacy
A significant treatment effect in favor of sildenafil
(P< 0.0001 vs placebo) was seen for Q3 and Q4 and
for the GEQ and the percentage of successful
attempts at sexual intercourse as reported in
patients’ event logs).8
Sildenafil treatment significantly improved all
five IIEF domains of male sexual function, compared
with placebo (Figure 1; P< 0.0001). Also, a signifi-
cant effect in favor of sildenafil treatment was seen
in each of the responses to the 15 questions of the
IIEF, at the week 12 end point.
Erectile function. In addition to significant in-
creases in both the frequency of penetration (Q3;
P< 0.0001) and the frequency of maintained erec-
tion after penetration (Q4; P< 0.0001), patients
receiving sildenafil reported significant improve-
ments in the ability to get an erection (Q1;
P< 0.0001), the frequency of erections hard enough
for penetration (Q2; P< 0.0001) and the ability to
maintain an erection until completion of sexual
intercourse (Q5; P< 0.0001), relative to patients
receiving placebo. Patients receiving sildenafil also
reported significantly greater self-confidence in
achieving and maintaining an erection (Q15), com-
pared with patients receiving placebo (P< 0.0001)
and compared with their level of self-confidence at
baseline (P< 0.05).
Orgasmic function. The sildenafil group experi-
enced significantly greater frequencies of both
ejaculation (Q9; P¼ 0.0004) and orgasm (Q10;
P< 0.0001), compared with the responses in the
placebo group, and for Q10, also compared with
baseline (P< 0.05).
Sexual desire. The sildenafil group had signifi-
cantly more frequent feelings of sexual desire (Q11;
P< 0.0001) and a significantly higher rating of
sexual desire (Q12; P¼ 0.0003), compared with the
placebo group, and compared with baseline
(P< 0.05 for both questions).
Intercourse satisfaction. Both the satisfaction (Q7;
P< 0.001) and enjoyment (Q8; P< 0.001) of sexual
intercourse were significantly increased in the silde-
nafil group, compared with the placebo group. Enjoy-
ment of sexual intercourse was also significantly
increased from baseline (P< 0.05). Sildenafil-treated
patients also attempted sexual intercourse more fre-
quently than placebo-treated patients (Q6; P¼ 0.05).
Overall satisfaction. The sildenafil-treated patients
were significantly more satisfied with their sex life
(Q13; P< 0.0001) and with their sexual relation-
ships with their partners (Q14; P< 0.0001) than
patients receiving placebo.
Safety
The safety data have been previously reported.8
Briefly, sildenafil was well tolerated; adverse events
led to treatment discontinuation in only one patient
who experienced severe transient headache while
receiving a 100-mg dose of sildenafil. The most
common adverse events considered related to silde-
nafil treatment by the investigator were flushing
Figure 1 Percent maximal domain scores ( standard error) of
the International Index of Erectile Function at baseline (n¼ 214)
and for men receiving sildenafil (n¼ 109) or placebo (n¼ 105) at
the end of 12 weeks of double-blind treatment by intent-to-treat
analysis.
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(8.9% vs 0% with placebo), headache (8.9% vs 3.3%
with placebo), dyspepsia (6.5% vs 0% with place-
bo), rash (3.2% vs 0% with placebo), dizziness
(3.2% vs 0.8% with placebo), abnormal vision (3.2%
vs 0.8% with placebo) and rhinitis (1.6% vs 0% with
placebo). The majority of the adverse events were
mild in intensity. No serious treatment-related
adverse events occurred.
Discussion
The present double-blind, placebo-controlled clini-
cal trial demonstrated that in Latin American men
with ED of a broad range of etiologies, treatment
with sildenafil at flexible doses on an as-needed
basis for 12 weeks significantly improved numerous
aspects of male sexual dysfunction. Consistent with
and in support of the significant improvements in
the primary efficacy variables reported previously
(Table 3),8 after 12 weeks of treatment, patients
receiving sildenafil showed significant improve-
ments in broad domains of male sexual function,
including erectile function, intercourse satisfaction,
orgasmic function, sexual desire and overall sexual
satisfaction, compared with patients receiving pla-
cebo. The greatest increases from baseline in mean
scores were observed in the erectile function
(þ 89%), intercourse satisfaction (þ 55%) and over-
all satisfaction (þ 93%) domains. Furthermore,
mean scores for each of the 15 items of the IIEF
were significantly higher for patients receiving
sildenafil than for those receiving placebo.
On the basis of assessment of erectile function
using the 15-item IIEF scale, Rosen et al determined
that the mean IIEF scores for these domains for
healthy men with no history of ED were approxi-
mately 25.8 for erectile function, 8.8 for orgasmic
function, 7.0 for sexual desire, 10.6 for intercourse
satisfaction and 8.6 for overall satisfaction.7
Rosen et al also demonstrated that, compared with
these healthy controls, men with ED had signifi-
cantly lower mean scores for all of these domains.
Consistent with these comparisons, in the present
study, the mean baseline scores for the study
patients were approximately 11.9 for erectile
function, 5.9 for orgasmic function, 6.8 for sexual
desire, 6.5 for intercourse satisfaction and 3.9 for
overall satisfaction. After 12 weeks of flexible-dose
sildenafil treatment, a highly significant improvement
was observed in each domain. At end point, the
corresponding mean scores for these five domains
(22.5, 8.3, 7.8, 10.1 and 7.6, respectively) approached
or exceeded the corresponding mean scores reported
for healthy men without ED.
These improvements in domain scores mirror
those reported by Dinsmore et al in a study of 111
men with ED of broad-spectrum etiology.3 In their
placebo-controlled, double-blind study, mean IIEF
scores after 12 weeks of treatment for patients
receiving flexible-dose sildenafil (25, 50 or 100 mg)
were significantly higher than for patients receiving
placebo for all 15 questions of the IIEF. Mean IIEF
scores for patients receiving sildenafil approached
those observed in age-matched healthy control
subjects, representing a ‘near normalization’ of
erectile function after 12 weeks of sildenafil treat-
ment. These findings provide evidence of the long-
term effectiveness of sildenafil.
The improvements in the IIEF domains observed
in the present study generally confirm the findings
of other double-blind, placebo-controlled, clinical
evaluations of flexible-dose sildenafil treatment in
men with ED of broad-spectrum etiology.2,10 Sexual
desire, however, appears to be variably affected by
sildenafil treatment. Similar to the present study,
the flexible-dose, placebo-controlled study reported
recently by Meuleman et al found sildenafil treat-
ment to be associated with a mean domain score for
sexual desire of 7.2 after 12 weeks (P¼ 0.04 vs
baseline) and 7.0 (P¼not significant vs baseline)
after 26 weeks of treatment, compared with a
baseline score of 6.3.10 As in the present study,
sildenafil treatment increased the mean sexual
desire domain score to within the normal range
(7.0),7 both at 12 and 26 weeks. However, a previous
flexible-dose study found no significant difference
in the mean sexual desire domain scores for
sildenafil and placebo groups after the same dura-
tion of treatment.2 This suggests that the increase in
sexual desire may occur secondary to improvements
in erectile function rather than as the result of a
direct effect of sildenafil on sexual desire or libido.
There is no current evidence to indicate that orally
administered sildenafil has effects in the brain.
Indeed, previous studies have found much less of
an increase in the sexual desire domain, compared
with other domains.2,11
Sildenafil treatment was well tolerated, despite
the use of the maximum dose of 100-mg by over half
Table 3 Mean scores ( standard error) for the frequency of penetration (IIEF Q3) and frequency of maintained erections after
penetration (IIEF Q4) at baseline and after 12 weeks of double-blind treatment with sildenafil or placebo, by intent-to-treat analysis
IIEF question Baseline (n¼ 214) Placebo (n¼105) Sildenafil (n¼109) P-value
Question 3 2.07 0.09 2.56 0.16 3.93 0.15 < 0.0001
Question 4 1.75 0.08 2.33 0.15 3.83 0.15 < 0.0001
IIEF¼ International Index of Erectile Function.
Adapted from Glina et al, 2001.8
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(57%) of the study patients at end point. Headache
and flushing were the most common adverse events
of sildenafil treatment, consistent with reports from
other flexible-dose, placebo-controlled studies,2,3,10
and during general clinical use of sildenafil.4,12
Adverse events rarely led to treatment discontinua-
tion; only one patient discontinued sildenafil treat-
ment at the maximum recommended dose (100 mg)
after experiencing a transient, severe headache.
In conclusion, the results of this flexible-dose
study demonstrate that sildenafil is an effective and
well-tolerated oral treatment for ED of broad-
spectrum etiology in Latin American men. The
results of this study also suggest that in this patient
population, sildenafil treatment can enhance male
sexual function to levels approaching those reported
in healthy controls with no history of ED.
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